| BUY | 47.090 | Don Reed | Likes the pharmaceuticals. This is one that he would favour investing in. They have defensive characteristics. This would be a 5 year or so hold. | 2008-08-28 | |
| PAST TOP PICK | 46.790 | Neil Wickham | (A Top Pick Mar 20/07. Down 10%.) Had a couple of problems with major drugs and doesn’t see this being resolved yet. Sold his holdings. | 2008-07-14 | |
| Comment | 45.850 | Norman Levine | UK-based international big pharmaceutical. Has drugs coming off of patent. 5.5% dividend should be safe. | 2008-02-26 | |
| DON'T BUY | 51.580 | David Baskin | He is not a player in the pharmaceutical industry. As soon as somebody comes up with a big drug, it instantly gets cloned by generics. Even FDA approved drugs are having adverse effects. | 2007-08-23 | |
| Comment | 52.640 | Don Reed | Have had some difficulties so there has been a sell off. Great depth in their management team. Reasonable pipeline. | 2007-07-12 | |
| BUY | 51.340 | Charles Lannon | Their patent expires this year. Are being evaluated, will probably sell.
Recommends Johnson & Johnson instead. JNJ-N
| 2007-06-07 | |
| SELL | 51.280 | Kenneth P. Norquay, CMT | A volatile uptrend. The five year chart shows a "double top" has broken below the valley between the double top, which is a signal to sell. | 2007-06-01 | |
| TOP PICK | 55.620 | Neil Wickham | Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend. | 2007-03-20 | |
| BUY | 53.130 | Paul Harris, CFA | Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run. | 2006-11-30 | |
| DON'T BUY | 53.270 | John Zechner | A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices. | 2006-11-08 | |
| PAST TOP PICK | 54.870 | David Driscoll | (A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend. | 2006-08-17 | |
| TOP PICK | 57.100 | David Driscoll | Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook. | 2006-05-08 | |
| BUY | 54.330 | Gavin Graham | 5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline. | 2006-03-20 | |
| BUY | 50.490 | Don Reed | The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management. | 2005-12-06 | |
| BUY | 39.300 | David Driscoll | Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India. | 2004-07-15 | |
| TOP PICK | 39.490 | David Driscoll | Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient. | 2004-03-11 | |
| WEAK BUY | 39.550 | Brad Willock | They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent. | 2003-09-03 | |
| BUY | 42.960 | Ray Steele | Likes, but prefers Johnson & Johnson. | 2002-10-15 | |
| BUY | 40.800 | David Driscoll | Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%. | 2002-06-25 | |
| BUY | 48.730 | David Driscoll | Prefers over US pharmaceuticals. Better situated globally. | 2002-03-08 | |
| TOP PICK | 48.180 | Arthur Heinmaa | Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget. | 2002-01-28 | |
| BUY | 55.840 | Arthur Heinmaa | Has a new drug, competing with Prozac. Also into biotechs, making good diversification. | 2001-08-07 | |
| BUY | 55.390 | Gavin Graham | Good merger. A safe holding. | 2001-06-26 | |
| BUY | 53.150 | David Driscoll | Bullet proof portfolio-large caps (40%) | 2001-03-27 | |
| PAST TOP PICK | 53.150 | David Driscoll | (Was a top pick on Oct 11 - Down 6%) but still likes it. | 2001-03-27 | |
| BUY | 55.310 | David Driscoll | A good merger making them the largest pharmaceutical | 2001-02-14 | |
Experts that have talked about Glaxosmithkline PLC
Rss Top Picks Feed
